FIG. 1



Effect of Increasing Amounts of Buffering Agent on Meloxicam Dissolution in the Presence or Absence of Cyclodextrin (120 Minutes)
25%
20%
15%
10%
5%
0%
25 mg K_2CO_3
50 mg K_2CO_3
100 mg K_2CO_3
150 mg K_2CO_3
Meloxicam
Meloxicam + Cyclodextrin

FIG. 2



Effects of Buffering Agents on Meloxicam Dissolution in the Presence or Absence of Cyclodextrin
100%
80%
60%
40%
20%
0%
150 mg K_2CO_3 @ 15 min
500 mg $NaHCO_3$ @ 15 min
150 mg K_2CO_3 @ 120 min
500 mg $NaHCO_3$ @ 120 min
Meloxicam
Meloxicam + Cyclodextrin

FIG. 3



Effects of Buffering Agents on Meloxicam Dissolution
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
15 minutes
120 minutes
Meloxicam
Meloxicam + K_2CO_3
Meloxicam + $NaHCO_3$

FIG. 4



Effects of Buffering Agents on Meloxicam Dissolution in the Presence of Cyclodextrin
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
15 minutes
120 minutes
Meloxicam/cyclodextrin
Meloxicam/cyclodextrin + K_2CO_3
Meloxicam/cyclodextrin + $NaHCO_3$

FIG. 5



Meloxicam Dissolution at 15 Minutes with K_2CO_3 and Cyclodextrin
35%
30%
25%
20%
15%
10%
5%
0%
Meloxicam
Meloxicam + Cyclodextrin
Meloxicam + K_2CO_3
Meloxicam + Cyclodextrin + K_2CO_3

FIG. 6



Meloxicam Dissolution at 120 Minutes with K_2CO_3 and Cyclodextrin
25%
20%
15%
10%
5%
0%
Meloxicam
Meloxicam + Cyclodextrin
Meloxicam + K_2CO_3
Meloxicam + Cyclodextrin + K_2CO_3

FIG. 7



Meloxicam Dissolution at 15 Minutes with NaHCO3 and Cyclodextrin
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Meloxicam
Meloxicam + Cyclodextrin
Meloxicam + NaHCO3
Meloxicam + Cyclodextrin + NaHCO3

FIG. 8



Meloxicam Dissolution at 120 Minutes with NaHCO3 and Cyclodextrin
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Meloxicam
Meloxicam + Cyclodextrin
Meloxicam + NaHCO3
Meloxicam + Cyclodextrin + NaHCO3

FIG. 9




Meloxicam Dissolution at 15 Minutes with Buffering Agents and Cyclodextrin
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Meloxicam
Meloxicam + Cyclodextrin
Meloxicam + K_2CO_3
Meloxicam + $NaHCO_3$
Meloxicam + Cyclodextrin + K_2CO_3
Meloxicam + Cyclodextrin + $NaHCO_3$

FIG. 10


Meloxicam Dissolution at 120 Minutes with Buffering Agents and Cyclodextrin
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Meloxicam
Meloxicam + Cyclodextrin
Meloxicam + K_2CO_3
Meloxicam + $NaHCO_3$
Meloxicam + Cyclodextrin + K_2CO_3
Meloxicam + Cyclodextrin + $NaHCO_3$



Mean Meloxicam Concentrations - Day 1
Bilayer Meloxicam
Mobic
ng/mL
2,500
2,000
1,500
1,000
500
Hours
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

FIG. 11



Meloxicam/Rizatriptan (20 mg meloxicam / 10 mg rizatriptan)
Mobic (15 mg meloxicam)
Mean Meloxicam Plasma Concentrations (ng/mL)
2500
2000
1500
1000
500
0
0
1
2
3
4
5
6
7
8
9
10
11
12
24
Hour

FIG. 12




Meloxicam/Rizatriptan (20 mg meloxicam / 10 mg rizatriptan)
Maxalt (10 mg rizatriptan)
Rizatriptan Plasma Concentrations (pg/mL)
30000
25000
20000
15000
10000
5000
0
0
1
2
3
4
5
6
7
8
9
10
11
12
Hour

FIG. 13


FIG. 14


Rapid Relief of Migraine Pain
P=0.009
vs. Rizatriptan
P=0.019
vs. Rizatriptan
P=0.040
vs. Rizatriptan
Subjects Reporting Pain Relief
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
0.5
1
1.5
2
4
Hour Post Dose
Placebo
MoSEIC Meloxicam
Rizatriptan
Meloxicam / Rizatriptan


Pain Freedom Rates Over Time
Percent of Subjects Achieving Pain Freedom
0
10
20
30
40
50
60
70
2 Hour
4 Hour
12 Hour
16 Hour
6.7
11.6
17.4
19.9
18.7
24.7
32.7
39.5
32.5
43.9
48.4
56.5
37.8
45.8
50.1
58.2
P<0.001
P<0.001
P=0.04
P<0.001
P<0.001
P=0.018
P<0.001
P<0.001
P=0.019
Placebo
MoSEIC Meloxicam
Rizatriptan
Meloxicam / Rizatriptan

FIG. 15

FIG. 16A



80% of subjects treated with Meloxicam/Rizatriptan who achieved pain freedom at Hour 2 maintained it through Hour 24

FIG. 16B






FIG. 17A



77% of subjects treated with Meloxicam/Rizatriptan who achieved pain freedom at Hour 2 maintained it through Hour 48

FIG. 17B





Reduced Use of Rescue Medication
Percentage of Subjects Who Took Rescue Medication through Hour 24
50%
40%
30%
20%
10%
0%
P<0.001
P<0.001
P<0.001
43.5%
35.1%
34.7%
23.0%
Placebo
MoSEIC Meloxicam
Rizatriptan
Meloxicam / Rizatriptan
77% of subjects receiving Meloxicam/Rizatriptan did not require rescue medication

FIG. 18